Cell Cure Neurosciences, a fully owned subsidiary of BioTime, Inc., is a biotechnology company focused on developing cell therapies for retinal and neural degenerative diseases. Our technology is based on human embryonic stem cells (hESC), which, for the first time in the history of medicine, open the door to the industrial-scale manufacture of any cell type in the human body. Cell Cure is using these powerful stem cells to manufacture a particular cell type in the retina called the retinal pigment epithelial (RPE) cell.
When RPE cells are lost due to aging, a disease called age-related macular degeneration (AMD) results. Our first product in development, OpRegen, contains hESC-derived RPE to treat AMD. Unlike currently marketed products designed to treat only the wet form of AMD (10% of AMD patients), OpRegen is being developed as a first-line therapy for the dry form of AMD (about 90% of AMD patients). Despite serving only the wet AMD market, the currently marketed products have achieved more than $5B in annual sales.
Cell Cure Neurosciences is conducting a Phase I/IIa clinical trial of OpRegen to treat the larger market of dry AMD, for which there is currently no FDA-approved therapeutic.